New Three Visit, Single Dose Migraine Study!
If you have between 2 to 8 migraines per month, you could participate in a study to help us learn about a new investigational medication being tested for the acute treatment of migraines.
Specifically, the Biohaven 301 study is a 3-visit, placebo-controlled migraine study of an investigational medication taken as needed for migraine headache in the form of a nasal spray.
You may qualify to participate if you:
- Are at least 18 years of age
- Have a history of migraine for 12 months or longer
- Have 2 to 8 migraine headaches per month
If you are interested, please contact us and we will perform a quick pre-screen over the phone, to see if you qualify for this study.
For more information, call or text Dr. Counihan at 617-875-0962 or if you prefer, you may email him at dcounihan@medvadis.com. Please include your contact information and the best time of day to contact you.
Our Medical Director, Egilius L.H. Spierings, MD PhD, is a neurologist, headache & face pain specialist, and pharmacologist. He has conducted clinical trial research since 1980. In addition to serving as a Sub-Investigator at MedVadis Research, Dr. Spierings is now also the Medical Director of the Boston Headache Institute at Boston PainCare.
Our General Director and Primary Investigator at Medvadis Research, David DiBenedetto, MD, is one of the founding partners of Boston PainCare and the Boston Headache Institute and serves as Boston PainCare’s Medical Director. Dr. DiBenedetto has more than 20 years of experience and specializes in interventional pain management and anesthesiology.